IDH2 and central nervous system cancer: In addition, recently, the WHO grading system of central nervous system tumors was updated to require genetic testing including IDH mutation, TERT promoter mutation, H3K27M mutation, 1p/19q codeletion for the precise diagnosis of gliomas.